Condition Directory

Gastric Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Gastric Cancer. Browse Gastric Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 25, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1089

Shown on this page

Current sort

How Gastric Cancer studies are organized in the registry

Gastric cancer studies are often registered together with gastroesophageal junction (GEJ) tumors, and many list both. HER2 status appears in this portfolio as well, marking a biomarker-defined subset. Including “gastroesophageal” in a query surfaces records that a plain “gastric” search can miss.

Terms that often appear in related listings

gastroesophageal junction GEJ HER2 advanced gastric

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 97–108 of 1,089 matching trials for Gastric Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Advanced Solid Tumor, Metastatic Colorectal Carcinoma, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Renal Cell Carcinoma
Interventions: FPI-2053, [111In]-FPI-2107, [225Ac]-FPI-2068; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 6
States / cities: Palo Alto, California • Chicago, Illinois • Omaha, Nebraska + 3 more

Conditions: NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
Interventions: TS-104; Drug
Lead sponsor: TwoStep Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Maumee, Ohio • Portland, Oregon • Fairfax, Virginia

Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Interventions: AB598, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 11
States / cities: Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more

Conditions: Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Lymphoma, Extranodal Marginal Zone Lymphoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Nemtabrutinib, Positron Emission Tomography, Rituximab; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer
Interventions: TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Albumin-Bound Paclitaxel; Drug
Lead sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 18
States / cities: Gilbert, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more

Conditions: Gastrointestinal Tract Malignancies
Interventions: Domvanalimab, Quemliclustat, Zimberelimab, Fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 12 more

Conditions: Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions: Cadonilimab, CAPOX regimen, Nivolumab, Placebo; Drug
Lead sponsor: Akeso; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 9 more

Conditions: Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer, Stomach Cancer, Cancer
Interventions: IM-1617; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 1 more

Conditions: Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma, Endometrial Adenocarcinoma, Ovarian Adenocarcinoma
Interventions: DBC-664; Biological
Lead sponsor: Duboce Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 6
States / cities: Denver, Colorado • Grand Rapids, Michigan • East Brunswick, New Jersey + 3 more

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
Interventions: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Zollinger Ellison Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1991
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pancreatic Cancer, Gastric Cancer, Hepatic Cancer, Colon Cancer, Rectal Cancer, Small Bowel Cancer
Interventions: Mobile health application and Fitbit + standard of care, Standard of care; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: New York, New York

About this Gastric Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Gastric Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Gastric Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Gastric Cancer clinical trials

How Gastric Cancer studies are organized in the registry

Filter and sort this condition

Live official records

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

DBC-664 in Adult Patients With Solid Tumors

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Evaluating Pancreatic Tumors in Patients With Zollinger-Ellison Syndrome

RCT of Mobile Apps & FitBit v. Usual Care

About this Gastric Cancer clinical trials directory page